GSK.L
Latest Trade
1,820.00GBpChange
-18.00(-0.98%)Volume
7,526,374Today's Range
-
1,846.0052 Week Range
-
1,851.15As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay
Previous Close | 1,838.00 |
|---|---|
Open | 1,831.80 |
Volume | 7,526,374 |
3M AVG Volume | 131.80 |
Today's High | 1,846.00 |
Today's Low | 1,813.40 |
52 Week High | 1,851.15 |
52 Week Low | 1,429.80 |
Shares Out (MIL) | 4,989.60 |
Market Cap (MIL) | 91,708.78 |
Forward P/E | -- |
Dividend (Yield %) | -- |
U.S. FDA Grants Priority Review To GSK's Multiple Myeloma Drug
U.S. FDA Grants Priority Review Of GSK's Belantamab Mafodotin For Patients With Relapsed Or Refractory Multiple Myeloma
Vectura Sees FY Rev, Adj. EBITDA At Least In Line With Its View
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
Executive Leadership
Jonathan Richard Symonds
Independent Non-Executive Chairman of the Board
Emma N. Walmsley
Chief Executive Officer, Executive Director
Iain James Mackay
Chief Financial Officer, Executive Director
Roger G. Connor
President - Vaccines
Brian McNamara
Chief Executive Officer - GSK Consumer Healthcare
Price To Earnings (TTM) | 19.58 |
|---|---|
Price To Sales (TTM) | 2.77 |
Price To Book (MRQ) | 7.79 |
Price To Cash Flow (TTM) | 11.00 |
Total Debt To Equity (MRQ) | 280.74 |
LT Debt To Equity (MRQ) | 210.95 |
Return on Investment (TTM) | 11.20 |
Return on Equity (TTM) | 7.30 |
British drugmaker GlaxoSmithKline may have harmed competition with payments it made to generic drugmakers to delay the launch of cheap copies of an antidepressant, according to an adviser to the European Court of Justice.
British drugmaker GlaxoSmithKline <GSK.L> may have harmed competition with payments it made to generic drugmakers to delay the launch of cheap copies of an antidepressant, according to an adviser to the European Court of Justice.
Drugmakers including Pfizer Inc <PFE.N>, GlaxoSmithKline PLC <GSK.L> and Sanofi SA <SASY.PA> are planning to hike U.S. list prices on more than 200 drugs in the United States on Wednesday, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.
GlaxoSmithKline's HIV drugs division ViiV Healthcare said on Saturday that the U.S. Food and Drug Administration declined to approve its long acting HIV injection.
In December 2017, U.S. District Judge Cynthia Rufe of Philadelphia seemingly drove a stake through the heart of litigation by two employee healthcare funds suing GlaxoSmithKline over its marketing of the diabetes drug Avandia. The plans, which sued back in 2010, alleged...
GlaxoSmithKline <GSK.L> said on Monday it had applied for U.S. approval for its experimental multiple myeloma drug that showed meaningful response in nearly a third of patients, setting up a battle against Johnson & Johnson <JNJ.N> and Genmab's Darzalex.
GlaxoSmithKline Plc said on Thursday its HIV unit has submitted a new drug application to the U.S. Food and Drug Administration seeking approval for fostemsavir, an experimental treatment for HIV in adults.
GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production.
GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a "step change" in production.
German science and technology company Merck KGaA <MRCG.DE> raised its full-year forecast for sales and adjusted earnings on Thursday after completing the takeover of semiconductor materials maker Versum Materials <VSM.N> in October.
GlaxoSmithKline <GSK.L> on Wednesday raised its annual profit forecast for the second time this year as sales of its shingles vaccine beat expectations and older medicines, including HIV treatments, continued to sell well.
GlaxoSmithKline Plc on Wednesday raised its annual profit forecast for the second time this year as soaring sales of its Shingles vaccine helped offset a hit from generic competition to its blockbuster asthma drug Advair.
GlaxoSmithKline Plc <GSK.L> said on Monday it has begun a late-stage study testing its experimental antibiotic in patients with urinary tract infections and gonorrhoea, a type of sexually transmitted infection.
GlaxoSmithKline said U.S. regulators had approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes with rival AstraZeneca.
GlaxoSmithKline said on Wednesday U.S. regulators approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes with rival AstraZeneca.
The U.S. Food and Drug Administration and international health authorities are investigating the safety of Zantac heartburn medicine, also sold generically as ranitidine, after finding a probable cancer-causing impurity in the drug.
GlaxoSmithKline will sell two travel vaccines to Bavarian Nordic for up to 955 million euros ($1.1 billion), the British firm said on Monday, as it looks to bolster its push into the lucrative cancer drug market.
GlaxoSmithKline Plc said on Monday it will sell two travel vaccines to Denmark-based biotechnology company Bavarian Nordic for an upfront payment of 301 million euros ($335.71 million).
GlaxoSmithKline <GSK.L> on Tuesday said it is recalling the popular heartburn medicine Zantac in all markets as a "precaution", days after the U.S. Food and Drug Administration found "unacceptable" levels of probable cancer-causing impurity in the drug.
GlaxoSmithKline Plc is recalling its heartburn medicine Zantac as a "precautionary measure" due to a probable cancer-causing impurity in the drug, Britain's medicines watchdog said on Tuesday.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.